Financials Gilead Sciences, Inc.

Equities

GILD

US3755581036

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 13:00:00 2024-11-29 EST			5-day change	1st Jan Change
92.58 ^USD	+0.18%		+2.65%	+14.28%

11-27	Gilead Sciences, Inc. Announces New England Journal of Medicine Publication of PURPOSE 2 Results	CI
11-22	UBS Raises Price Target on Gilead Sciences to $96 From $70, Maintains Neutral Rating	MT

Projected Income Statement: Gilead Sciences, Inc.

income-statement-evolution-chart GILEAD-SCIENCES-INC

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Net sales ¹	22,449	24,689	27,305	27,281	27,116	28,303	28,282	29,153
Change	-	9.98%	10.6%	-0.09%	-0.6%	4.38%	-0.07%	3.08%
EBITDA ¹	12,468	13,184	14,598	14,283	13,177	10,714	14,625	15,001
Change	-	5.74%	10.73%	-2.16%	-7.74%	-18.69%	36.5%	2.57%
EBIT ¹	11,064	11,704	12,548	12,180	10,484	8,214	12,387	12,878
Change	-	5.78%	7.21%	-2.93%	-13.92%	-21.65%	50.81%	3.96%
Interest Paid ¹	-995	-984	-1,001	-935	-944	-962.8	-939.3	-904.1
Earnings before Tax (EBT) ¹	5,160	1,669	8,278	5,814	6,859	497.9	8,429	8,908
Change	-	-67.66%	395.99%	-29.77%	17.97%	-92.74%	1,592.87%	5.68%
Net income ¹	5,386	123	6,225	4,592	5,665	259.3	6,921	7,527
Change	-	-97.72%	4,960.98%	-26.23%	23.37%	-95.42%	2,569.2%	8.75%
Announcement Date	2/4/20	2/4/21	2/1/22	2/2/23	2/6/24	-	-	-

¹USD in Million

Estimates

Fiscal Period: Diciembre	2019 Q4	2020 Q1	2020 Q2	2020 Q3	2020 Q4	2021 Q1	2021 Q2	2021 Q3	2021 Q4	2022 Q1	2022 Q2	2022 Q3	2022 Q4	2023 Q1	2023 Q2	2023 Q3	2023 Q4	2024 Q1	2024 Q2	2024 Q3	2024 Q4	2025 Q1	2025 Q2	2025 Q3	2025 Q4
Net sales ¹	5,879	5,548	5,143	6,577	7,421	6,423	6,217	7,421	7,244	6,590	6,260	7,042	7,389	6,352	6,599	7,051	7,115	6,686	6,954	7,545	7,163	6,641	6,859	7,294	7,486
Change	-	-5.63%	-7.3%	27.88%	12.83%	-13.45%	-3.21%	19.37%	-2.39%	-9.03%	-5.01%	12.49%	4.93%	-14.03%	3.89%	6.85%	0.91%	-6.03%	4.01%	8.5%	-5.07%	-7.28%	3.27%	6.35%	2.64%
EBITDA ¹	2,662	3,114	2,344	3,807	3,919	3,959	3,695	4,902	2,042	4,049	3,195	3,811	3,227	2,883	3,258	3,908	3,427	-427	3,959	3,948	3,197	-	-	-	-
Change	-	16.98%	-24.73%	62.41%	2.94%	1.02%	-6.67%	32.67%	-58.34%	98.29%	-21.09%	19.28%	-15.32%	-10.66%	13.01%	19.95%	-12.31%	-	-	-0.28%	-19.01%	-100%	-	-	-
EBIT ¹	2,312	2,765	1,995	3,452	3,492	3,486	3,176	4,379	1,507	3,524	2,670	3,286	2,699	2,243	2,277	3,224	2,739	-1,117	3,265	3,258	2,893	2,809	2,976	3,278	3,358
Change	-	19.59%	-27.85%	73.03%	1.16%	-0.17%	-8.89%	37.88%	-65.59%	133.84%	-24.23%	23.07%	-17.86%	-16.9%	1.52%	41.59%	-15.04%	-	-	-0.21%	-11.2%	-2.89%	5.92%	10.15%	2.44%
Charge d'intérêts ¹	-243	-241	-240	-236	-267	-257	-256	-250	-238	-238	-242	-229	-227	-230	-230	-232	-252	-254	-237	-238	-234.4	-224.1	-219.1	-219.1	-219.1
Earnings before Tax (EBT) ¹	1,901	2,003	-2,973	825	1,814	2,264	1,817	3,438	759	-152	1,503	2,432	2,031	1,300	1,588	2,318	1,653	-4,486	2,053	956	2,043	-	-	-	-
Change	-	5.37%	-	-	119.88%	24.81%	-19.74%	89.21%	-77.92%	-	-	61.81%	-16.49%	-35.99%	22.15%	45.97%	-28.69%	-	-	-53.43%	113.66%	-100%	-	-	-
Net income ¹	2,696	1,551	-3,339	360	1,551	1,729	1,522	2,592	382	19	1,144	1,789	1,640	1,010	1,045	2,180	1,429	-4,170	1,614	1,253	1,577	1,569	1,729	1,901	2,008
Change	-	-42.47%	-	-	330.83%	11.48%	-11.97%	70.3%	-85.26%	-95.03%	5,921.05%	56.38%	-8.33%	-38.41%	3.47%	108.61%	-34.45%	-	-	-22.37%	25.82%	-0.51%	10.24%	9.95%	5.6%
Announcement Date	2/4/20	4/30/20	7/30/20	10/28/20	2/4/21	4/29/21	7/29/21	10/28/21	2/1/22	4/28/22	8/2/22	10/27/22	2/2/23	4/27/23	8/3/23	11/7/23	2/6/24	4/25/24	8/8/24	11/6/24	-	-	-	-	-

¹USD in Million

Estimates

Forecast Balance Sheet: Gilead Sciences, Inc.

balance-sheet-analysis-chart GILEAD-SCIENCES-INC

Fiscal Period: Diciembre	2019	2020	2021	2022	2023	2024	2025	2026
Net Debt ¹	241	30,879	27,449	18,845	17,723	17,688	13,368	8,355
Change	-	12,712.86%	-11.11%	-31.35%	-5.95%	-0.2%	-24.42%	-37.5%
Announcement Date	2/4/20	2/4/21	2/1/22	2/2/23	2/6/24	-	-	-

¹USD in Million

Estimates

Cash Flow Forecast: Gilead Sciences, Inc.

Fiscal Period: Diciembre	2019	2020	2021	2022	2023	2024	2025	2026
CAPEX ¹	825	650	579	728	585	581	569.1	578.3
Change	-	-21.21%	-10.92%	25.73%	-19.64%	-0.68%	-2.05%	1.62%
Free Cash Flow (FCF) ¹	8,319	7,518	10,805	8,344	7,421	8,138	10,492	10,834
Change	-	-9.63%	43.72%	-22.78%	-11.06%	9.66%	28.92%	3.26%
Announcement Date	2/4/20	2/4/21	2/1/22	2/2/23	2/6/24	-	-	-

¹USD in Million

Estimates

Forecast Financial Ratios: Gilead Sciences, Inc.

Fiscal Period: Diciembre	2019	2020	2021	2022	2023	2024	2025	2026
Profitability
EBITDA Margin (%)	55.54%	53.4%	53.46%	52.36%	48.59%	37.86%	51.71%	51.46%
EBIT Margin (%)	49.29%	47.41%	45.95%	44.65%	38.66%	29.02%	43.8%	44.17%
EBT Margin (%)	22.99%	6.76%	30.32%	21.31%	25.3%	1.76%	29.8%	30.56%
Net margin (%)	23.99%	0.5%	22.8%	16.83%	20.89%	0.92%	24.47%	25.82%
FCF margin (%)	37.06%	30.45%	39.57%	30.59%	27.37%	28.75%	37.1%	37.16%
FCF / Net Income (%)	154.46%	6,112.2%	173.57%	181.71%	131%	3,138.46%	151.59%	143.93%
Profitability
ROA	8.6%	0.19%	9.13%	13.97%	13.49%	3.2%	13.57%	13.57%
ROE	38.32%	43.84%	46.79%	43.33%	38.46%	25.29%	41.74%	36.28%
Financial Health
Leverage (Debt/EBITDA)	0.02x	2.34x	1.88x	1.32x	1.34x	1.65x	0.91x	0.56x
Debt / Free cash flow	0.03x	4.11x	2.54x	2.26x	2.39x	2.17x	1.27x	0.77x
Capital Intensity
CAPEX / Current Assets (%)	3.67%	2.63%	2.12%	2.67%	2.16%	2.05%	2.01%	1.98%
CAPEX / EBITDA (%)	6.62%	4.93%	3.97%	5.1%	4.44%	5.42%	3.89%	3.86%
CAPEX / FCF (%)	9.92%	8.65%	5.36%	8.72%	7.88%	7.14%	5.42%	5.34%
Items per share
Cash flow per share ¹	7.16	6.467	9.021	7.189	6.364	6.625	8.085	9.093
Change	-	-9.68%	39.48%	-20.31%	-11.47%	4.1%	22.05%	12.47%
Dividend per Share ¹	2.52	2.72	2.84	2.92	3	3.066	3.226	3.364
Change	-	7.94%	4.41%	2.82%	2.74%	2.19%	5.24%	4.28%
Book Value Per Share ¹	17.79	14.43	16.8	17.01	18.08	15.57	17.84	20.31
Change	-	-18.9%	16.41%	1.25%	6.32%	-13.92%	14.6%	13.84%
EPS ¹	4.22	0.1	4.93	3.64	4.5	0.1454	5.663	6.144
Change	-	-97.63%	4,830%	-26.17%	23.63%	-96.77%	3,793.77%	8.49%
Nbr of stocks (in thousands)	1,265,146	1,253,528	1,254,384	1,254,244	1,246,042	1,246,266	1,246,266	1,246,266
Announcement Date	2/4/20	2/4/21	2/1/22	2/2/23	2/6/24	-	-	-